Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1281 • ACR Convergence 2025
Ethnic Disparities in Mental Health Screening, Diagnoses, and Outcomes in Patients with Childhood-Onset Systemic Lupus Erythematosus
Alicia Tran¹, Indrani Das², Zhaoyu Ding³, Daniela Dominguez⁴, Sefi Kronenberg⁵, Lawrence Ng⁶, Alene Toulany¹, Gwyneth Zai⁷, Deborah Levy¹, Andrea Knight⁸ and Linda Hiraki¹, ¹The Hospital for Sick Children, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³SickKids Research Institute, Toronto, ON, Canada, ⁴The Hospital for Sick Children, Toronto, Canada, ⁵Holland Bloorview Kids Rehabilitation Hospital, Toronto, ON, Canada, ⁶The Hospital for Sick Children, Toronto, Canada, Toronto, ON, Canada, ⁷Centre for Addiction & Mental Health, Toronto, ON, Canada, ⁸Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Patients with childhood-onset systemic lupus erythematosus (cSLE) face higher risks of depression and anxiety compared to healthy peers. In 2022, standardized mental health (MH)…
Abstract Number: 1470 • ACR Convergence 2025
Why Do Some Lupus Patients Skip Their Mycophenolate Mofetil? A Multi-Factorial Assessment of Patient Compliance
Nidaa Bukhari¹, Ali Rizvi¹, Jian sun¹, Zerai Manna², Paul Schaughency³, Suraj Rajasimhan⁴ and Sarfaraz Hasni¹, ¹National Institutes of Health, BETHESDA, MD, ²NIH, Bethesda, MD, ³NIAID, NIH, Bethesda, MD, ⁴National Institutes of Health, Columbia, MD
Background/Purpose: Nonadherence to medication is a significant confounder in assessing treatment efficacy for systemic lupus erythematosus (SLE), with rates reported up to 75% depending on…
Abstract Number: 1487 • ACR Convergence 2025
Whole Health Empowerment for Endotypes of Lupus (WHEEL) Program: User Testing Findings on Feasibility, Acceptability, and Opportunities for Intervention Refinement
Jennifer Rogers¹, Amanda Eudy², Connor Drake³, Tamara Somers⁴, David Pisetsky⁵, Christie Clipper⁶, Ralph Snyderman⁷, Anna Batsakes⁶, Leigh Saner⁶, Dana Burshell³, Mithu Maheswaranathan⁴, Lisa Criscione-Schreiber⁴, Rebecca Sadun⁸, Nathaniel Harris⁵, Kai Sun⁸, Kelsey Dunn⁶, Jenny Herndon⁶, Vonne Jacobs⁶ and Megan Clowse⁹, ¹Duke, Durham, NC, ²Duke University, Raleigh, NC, ³Duke University School of Medicine, Durham, ⁴Duke University School of Medicine, Durham, NC, ⁵Duke University Medical Center, Durham, NC, ⁶Duke University, Durham, ⁷Duke Center for Personalized Health Care, Durham, NC, ⁸Duke University, Durham, NC, ⁹Duke University, Chapel Hill, NC
Background/Purpose: To improve quality of life (QoL) in individuals with SLE, we developed the Whole Health Empowerment for Endotypes of Lupus (WHEEL) program—a 4-month, biweekly,…
Abstract Number: 1504 • ACR Convergence 2025
High prevalence of clonal hematopoiesis of indeterminate potential (CHIP) somatic mutations in a cohort of 1,073 SLE participants
Richard Oppong¹, Joanne Nititham², Ashira Blazer³, Manuel Ugarte-Gil⁴, Jinoos Yazdany⁵, Maria Dall'Era⁶, Alexander Bick⁷, Lindsey Criswell² and Cristina Lanata⁸, ¹National Institutes of Health, Bethesda, MD, ²NIH/NHGRI, Bethesda, MD, ³University of Maryland Baltimore, Baltimore, Maryland, ⁴Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas, Universidad Científica del Sur, Lima, Peru; Hospital Guillermo Almenara Irigoyen, EsSalud, Lima, Peru, Lima, Peru, ⁵UCSF, San Francisco, CA, ⁶Division of Rheumatology, University of California, San Francisco, CA, ⁷Vanderbilt University, Nashville, TN, ⁸NIH/NHGRI, Bethesda
Background/Purpose: Clonal hematopoiesis of indeterminate potential (CHIP) is characterized by the presence of somatic mutations in hematopoietic stem cells that lead to the expansion of…
Abstract Number: 1520 • ACR Convergence 2025
Long-Term Effects of Obinutuzumab on Kidney Function in Lupus Nephritis
Bahtiyar Toz¹, Himanshu Vashistha² and Richard Furie³, ¹Zucker School of Medicine at Hofstra/ Northwell, Queens, NY, ²Northwell Health, Great Neck, NY, ³Division of Rheumatology, Northwell Health, Great Neck, NY
Background/Purpose: Biologic treatments for lupus nephritis (LN) have improved short-term outcomes. Obinutuzumab (OBI), an anti-CD20 monoclonal antibody, demonstrated efficacy in the NOBILITY and REGENCY trials;…
Abstract Number: 1538 • ACR Convergence 2025
Safety, Pharmacodynamics, and Efficacy of a Novel Plasmacytoid Dendritic Cells Targeting Antibody in Healthy Adults and Patients with SLE or Cutaneous Lupus Erythematosus with Active Skin Lesions: A First-In-Human Study of KK4277
Minoru Hasegawa¹, Jun Kinoshita², Shigeki Otsubo³, Kana Yamada³ and Ehsanollah Esfandiari⁴, ¹Division of Medicine, University of Fukui, Yoshida-gun, Fukui, Japan, ²Kyowa Kirin Co., Ltd., Chiyoda-ku, Tokyo, Japan, ³Kyowa Kirin Co., Ltd., Tokyo, Japan, ⁴Kyowa kirin International plc, London, United Kingdom
Background/Purpose: Plasmacytoid dendritic cells (pDCs) are known to be the main source of type 1 interferon (IFN), which is the cause of various autoimmune diseases.…
Abstract Number: 1639 • ACR Convergence 2025
Concordance of Self-Reported Physical Functioning and Physical Performance in SLE: A Cross-Cohort Analysis
Laura Plantinga¹, Mrinalini Dey², Jessica Fitzpatrick³, Maria Dall'Era⁴, Charmayne Dunlop-Thomas⁵, Courtney Hoge⁵, S. Sam Lim⁶, C. Barrett Bowling⁷, Jinoos Yazdany³ and Patti Katz⁸, ¹University of California, San Francisco, San Francisco, CA, ²Centre for Rheumatic Diseases, King's College London, London, United Kingdom, ³UCSF, San Francisco, CA, ⁴Division of Rheumatology, University of California, San Francisco, CA, ⁵Emory University, Atlanta, GA, ⁶Emory University School of Medicine, Atlanta, GA, ⁷Duke University, Durham, NC, ⁸UCSF, San Rafael, CA
Background/Purpose: Assessment of self-reported physical functioning is common in SLE and essential for high-quality SLE care. However, because many factors may influence self-reported physical function…
Abstract Number: 1719 • ACR Convergence 2025
Impact of SGLT2 Inhibitors on Cardiovascular Events, Mortality, and Lupus Nephritis in Patients with Systemic Lupus Erythematosus and Diabetes: Retrospective Cohort Study
Rusudan Tskitishvili¹, Abdallah Hussein², Nanuka Tsibadze³, Shatha Shahwan⁴ and Priju Varghese², ¹Virtua Health, Camden, NJ, ²Virtua Health, Camden, ³Jefferson Health - Einstein, Philadelphia, PA, ⁴Jordan University of Science and Technology, Jordan
Background/Purpose: Systemic lupus erythematosus (SLE) is associated with increased risks of cardiovascular events, renal complications, and premature mortality. Sodium-glucose co-transporter-2 (SGLT2) inhibitors have shown cardiorenal…
Abstract Number: 1831 • ACR Convergence 2025
Distinct Proteomic Signature Predicts Post-MMF Withdrawal Flares in Systemic Lupus Erythematosus Patients
Christian Wright¹, Miles Smith², Rufei Lu², Catriona Wagner³, Aleksandra Bylinska², Carla Guthridge², Nicholas Domingez², Susan Macwana², Wade DeJager⁴, Marci Beel⁵, Joan Merrill⁶, Eliza Chakravarty², Ellen Goldmuntz⁷, Study Team ALE⁰⁶ Clinical⁸, Judith James² and Joel Guthridge², ¹University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, Oklahoma city, OK, ³Oklahoma Medical Research Foundation, Santa Cruz, CA, ⁴Oklahoma Medical Research Foundation, Oklahoma City, ⁵Oklahoma Medical Research Foun, Oklahoma City, OK, ⁶Oklahoma Medical Research Foundation, Oklahoma City ⁷³¹⁰⁴, OK, ⁷NIAID/ NIH, Washington, DC, ⁸Autoimmunity Center of Excellence, Oklahoma City, OK
Background/Purpose: : Systemic Lupus Erythematosus (SLE) follows a characteristic relapsing-remitting course with unpredictable flares interspersed with periods of relative quiescence. Mycophenolate mofetil (MMF) has emerged…
Abstract Number: 1850 • ACR Convergence 2025
First American SLE patients demonstrate enhanced lipid metabolism and B cell activation by high-content proteomic analyses
Rufei Lu¹, Tayte Stephens², Carla Guthridge¹, Miles Smith¹, Joseph Kheir¹, Cristina Arriens¹, Joan Merrill³, Marci Beel⁴, Susan Macwana¹, Wade DeJager⁵, Nicholas Domingez¹, Teresa Aberle¹, Joel Guthridge¹ and Judith James¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²University of Oklahoma Health Science Center, Oklahoma City, OK, ³Oklahoma Medical Research Foundation, Oklahoma City ⁷³¹⁰⁴, OK, ⁴Oklahoma Medical Research Foun, Oklahoma City, OK, ⁵Oklahoma Medical Research Foundation, Oklahoma City
Background/Purpose: Systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) are autoimmune diseases with overlapping yet distinct immunopathologies. Proteomic profiling of soluble plasma factors can reveal…
Abstract Number: 1931 • ACR Convergence 2025
COSMOS Prevalence of aTTP in SLE
Nisha Sapkota¹, Yevheniia Andriushchenko², Saadia Malik², Sarang Choi² and Sima Terebelo², ¹Interfaith Medical Center, One Broolyn Health, Brooklyn, NY, ²Brookdale Hospital Medical Center, One Brooklyn Health, Brooklyn
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune disease with diverse manifestations, including thrombotic thrombocytopenic purpura (TTP), a life-threatening hematologic disorder. The pathogenesis of…
Abstract Number: 2209 • ACR Convergence 2025
Pregnancy outcomes in Systemic Lupus Erythematosus: Insights from a multicenter Spanish Study on the impact of antiphospholipid antibodies and APS
cristiana Sieiro¹, Jose Ordas Martínez², Ana Merino³, Helena Amar Muñoz⁴, Stefanie Burger⁵, Ignacio Braña Abascal⁵, Carmen Jose Mendéz⁶, Raquel Dos Santos Sobrín⁷, Jose Luis Puga Guzman⁷, Ricardo Blanco⁸ and Víctor Taboada Martínez³, ¹Univrsity of Manchester, Manchester, United Kingdom, ²Complejo Asistencial Universitario de León, León, Spain, ³Hospital Universitario Marqués de Valdecilla, Santader, Spain,, Santander, Spain, ⁴Hospital General Universitario Gregorio Marañón, Rheumatology, Madrid, Spain, Madrid, Spain, ⁵Hospital Universitario Central de Asturias, Rheumatology, Oviedo, Spain, Oviedo, Spain, ⁶Complexo Hospitalario Universitario A Coruña, Rheumatology, A Coruña, Spain, Coruña, Spain, ⁷Hospital Universitario de Santiago de Compostela, Rheumatology, Santiago de Compostela,, Santiago de Compostela, Spain, ⁸Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain
Background/Purpose: Pregnancy in patients with systemic lupus erythematosus (SLE) is associated with significant maternal and obstetric risks, particularly in the context of antiphospholipid syndrome (APS).…
Abstract Number: 2381 • ACR Convergence 2025
Renal Tubular Complement C9 Deposition is Linked to Tubulointerstitial Fibrosis and Progression to Chronic Kidney Disease in Lupus Nephritis
Angela Lu¹, Daming Shao², Ying Jin¹, Luis Chiriboga³, Ming Wu⁴, James Pullman⁵, Anna Broder⁶ and Shudan Wang⁵, ¹Albert Einstein College of Medicine, Bronx, NY, ²University of Chicago, Chicago, IL, ³NYU Langone Medical Center, New York City, ⁴Northwell Health, New Hyde Park, ⁵Montefiore Medical Center, Bronx, NY, ⁶Hackensack University Medical Center, Hackensack, NJ
Background/Purpose: The complement system is known to play a central role in the pathogenesis of lupus nephritis (LN), one of the most severe manifestations of…
Abstract Number: 2397 • ACR Convergence 2025
Analytical Performance of a Fully Automated Multiplexed Microarray Immunoassay for the Simultaneous Detection of Fifteen Autoantibodies Associated with Connective Tissue Diseases in a Reference Laboratory in Southern France
Guillaume Nardella¹, Gerber Gomez², Christian Fischer² and Claire Monat¹, ¹Inovie Labosud Provence, Specialized Autoimmunity Analyses, Marseille, France, ²Scientific & Medical Affairs, AliveDx Suisse SA, Eysins, Switzerland
Background/Purpose: Autoantibodies are key diagnostic markers in autoimmune connective tissue diseases (CTD). Conventional testing often requires multiple single-measurand assays, which can be labor-intensive and time-consuming.…
Abstract Number: 2415 • ACR Convergence 2025
Evaluating the Readability and Comprehension of Patient Education Materials for Systemic Lupus Erythematosus (SLE) Available Online
Nagoor Shaik, Ugochukwu Nweke and Meenakshi Jolly, Rush University, Chicago
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic multisystemic autoimmune disease that had multidimensional adverse effects on patients lives, and preferentially inflicts young women, specially…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].